Shares of Mediwound Ltd (NASDAQ:MDWD) have received an average rating of “Buy” from the eight analysts that are covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $9.83.
A number of brokerages have issued reports on MDWD. Wells Fargo cut their price target on shares of Mediwound from $9.00 to $8.00 and set an “outperform” rating on the stock in a research note on Tuesday. ValuEngine raised Mediwound from a “strong sell” rating to a “sell” rating in a research report on Saturday, November 25th. Zacks Investment Research downgraded Mediwound from a “buy” rating to a “hold” rating in a research report on Tuesday, November 21st. Finally, Oppenheimer set a $10.00 price objective on Mediwound and gave the stock a “buy” rating in a research report on Friday, December 8th.
Several institutional investors have recently made changes to their positions in MDWD. Renaissance Technologies LLC grew its position in shares of Mediwound by 18.2% during the fourth quarter. Renaissance Technologies LLC now owns 100,600 shares of the biopharmaceutical company’s stock worth $448,000 after buying an additional 15,500 shares in the last quarter. Wells Fargo & Company MN grew its position in shares of Mediwound by 84.6% during the fourth quarter. Wells Fargo & Company MN now owns 101,189 shares of the biopharmaceutical company’s stock worth $450,000 after buying an additional 46,366 shares in the last quarter. Nationwide Fund Advisors acquired a new position in shares of Mediwound during the third quarter worth about $1,538,000. Alyeska Investment Group L.P. acquired a new position in shares of Mediwound during the third quarter worth about $2,140,000. Finally, Meitav Dash Investments Ltd. acquired a new position in shares of Mediwound during the fourth quarter worth about $2,184,000. 32.75% of the stock is owned by institutional investors and hedge funds.
Mediwound (NASDAQ:MDWD) last issued its quarterly earnings results on Monday, March 19th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.16) by $0.08. The company had revenue of $0.53 million for the quarter, compared to analyst estimates of $0.65 million. Mediwound had a negative net margin of 887.38% and a negative return on equity of 286.65%. equities analysts predict that Mediwound will post -0.69 earnings per share for the current year.
Mediwound Company Profile
MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.
Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.